SLN Earnings

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Published August 07, 2025 at 11:30 AM

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the second quarter ended June 30, 2025, and reviewed recent business highlights. “The updated data we presented at EHA this past quarter were highly encouraging and supportive of the therapeutic potential of divesiran as a first-in-class siRNA in PV,” said Craig Tooman, Pres

Related Questions

How does the company’s R&D spend as a percentage of revenue compare to other siRNA peers such as Alnylam or Dicerna? Are there any upcoming catalysts (e.g., conference presentations, data releases) that could drive the stock price in the near term? When is the next data read‑out or regulatory filing for divesiran in polycythemia vera expected? Did the company update its guidance for Q3 or full‑year 2025 earnings and cash flow? What are the implications of the recent EHA data on the probability of success for divesiran’s development program? What is the estimated market size for siRNA therapies in PV and related hematologic indications? How did the second‑quarter revenue and net loss compare to analyst consensus estimates? What is the current cash balance and projected cash‑burn rate, and how many months of runway does the company have? Are there any new partnership, licensing, or co‑development agreements that could impact future revenue streams? What regulatory hurdles or FDA/EMA milestones could affect the timeline to approval for divesiran? How might the Q2 results influence valuation multiples (e.g., EV/EBITDA, price‑to‑sales) for SLN compared to its peers?